SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Sodium chloride (0.9%) provides isotonic concentration of sodium and chloride ions to maintain extracellular fluid volume and osmolarity. Potassium chloride (0.22%) provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
| Metabolism | Electrolytes (sodium, potassium, chloride) are not metabolized; they are excreted primarily by the kidneys. |
| Excretion | Renal: Sodium >95% (glomerular filtration and variable tubular reabsorption); Potassium >90% (glomerular filtration and tubular secretion/reabsorption). Fecal <5%. |
| Half-life | Not applicable (endogenous substances); distribution half-life ~1–2 hours for infused dose; clinical context: no true elimination half-life due to homeostatic regulation; steady-state achieved with continuous infusion. |
| Protein binding | Sodium: negligible; Potassium: negligible. |
| Volume of Distribution | Sodium: 0.35–0.45 L/kg (extracellular fluid); Potassium: 0.4–0.5 L/kg (total body water with predominant intracellular distribution, but initial distribution volume reflects extracellular space). |
| Bioavailability | IV: 100% (sodium and potassium); no oral form for this combination; enteral or topical bioavailability not applicable for IV route. |
| Onset of Action | 0.9% NaCl: immediate upon IV infusion; 0.22% KCl: onset of potassium effect within 15–30 minutes after IV infusion. |
| Duration of Action | While infusion continues; effects persist for minutes to hours after cessation depending on compartment re-equilibration; continuous infusion required to maintain electrolyte balance. |
Intravenous infusion; typical adult dose is 1-2 L over 24 hours, titrated to fluid and electrolyte needs. Maximum rate 1 L/hour under controlled conditions.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <10 mL/min: reduce volume to 500-1000 mL/24h and monitor potassium closely. GFR 10-50 mL/min: standard dosing with monitoring. |
| Liver impairment | No dose adjustment required; monitor potassium in severe hepatic impairment (Child-Pugh C) due to risk of hyperkalemia. |
| Pediatric use | Weight-based: 0.9% sodium chloride/0.22% potassium chloride at 2-10 mL/kg/hour; adjust based on serum electrolytes and fluid balance. |
| Geriatric use | Use lower initial infusion rates (e.g., 0.5-1 L over 24 hours) and monitor for fluid overload and hyperkalemia due to decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Considered compatible with breastfeeding. Sodium and potassium are normal milk constituents; M/P ratio not applicable as these are endogenous ions. No adverse effects reported in nursing infants. |
| Teratogenic Risk | No evidence of teratogenicity in any trimester when used appropriately. Both sodium chloride and potassium chloride are essential electrolytes; adverse fetal effects are only anticipated with severe maternal electrolyte disturbances. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Hypernatremia","Fluid overload states (e.g., congestive heart failure, pulmonary edema)","Severe renal impairment with oliguria or anuria"]
| Precautions | ["Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload.","Monitor serum electrolytes, renal function, and acid-base balance regularly.","Rapid administration of potassium can cause fatal hyperkalemia; avoid bolus injection.","Use with caution in patients with hyperkalemia, acute dehydration, or concurrent use of potassium-sparing diuretics."] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes, renal function, and fluid balance periodically. In pregnancy, assess for signs of fluid overload or electrolyte imbalance; fetal heart rate monitoring may be indicated if maternal condition requires intensive therapy. |
| Fertility Effects | No known effects on fertility. This solution does not interfere with reproductive function. |